Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Ixekizumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-120
Last updated

Report documents

  1. Extract of dossier assessment

    Ixekizumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 260 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-120_en
    Download file : Extract of dossier assessment (PDF document, 260 kB, EN, not accessible)

  2. Dossier assessment

    Ixekizumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 448 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-120
    Download file : Dossier assessment (PDF document, 448 kB, DE, not accessible)

Dossier assessment

Indication:

Children and adolescents from 6 years of age with active juvenile psoriatic arthritis and a body weight of at least 25 kg who have had an inadequate response to, or who are intolerant of, conventional therapy

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A25-120
Commission
Commission awarded on 25.09.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Skin and hair
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-120_en

Connected Projects

  1. Dossier assessment

    Ixekizumab (spondylitis and spondyloarthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-66
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Ixekizumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-65
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Ixekizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A18-14
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Ixekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A17-07
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Ixekizumab (enthesitis-related arthritis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-121
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page